Compounds > 4-aminobenzoic acid

4-aminobenzoic acid and rg7388

4-aminobenzoic acid has been researched along with rg7388 in 55 studies

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's40 (72.73)24.3611
2020's15 (27.27)2.80

Authors

AuthorsStudies
Bartkovitz, D; Chu, XJ; Ding, Q; Filipovic, ZM; Glenn, K; Graves, B; Higgins, B; Janson, C; Jiang, N; Liu, JJ; Packman, K; Podlaski, F; Ross, TM; Tovar, C; Vassilev, LT; Zhang, J; Zhang, Z1
Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A1
Berry, P; Chen, L; Del Bello, F; Halliday, GC; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Piergentili, A; Rousseau, RF; Tweddle, DA; Zhao, Y1
Bartkovitz, D; Chu, XJ; Ding, Q; Filipovic, ZM; Glenn, K; Graves, B; Higgins, B; Janson, C; Jiang, N; Liu, JJ; Luk, KC; Packman, K; Tovar, C; Vassilev, LT; Zhang, J; Zhang, Z1
Bondra, K; Chronowski, C; Houghton, PJ; Kurmasheva, RT; Leasure, J; Middleton, S; Mo, X; Phelps, D; Seum, S; Wang, D1
Chen, L; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Rousseau, RF; Tweddle, DA1
Golding, BT; Hardcastle, IR; Zhang, B1
Allo, G; Hai, J; Ludkovski, O; Ng, C; Sakashita, S; Shepherd, FA; Tsao, MS1
Chaire, V; Chibon, F; Coindre, JM; Hostein, I; Italiano, A; Lagarde, P; Laroche, A; Lesluyes, T; Lucchesi, C; Neuville, A; Tran-Cong, K1
Kim, ES; Shohet, JM1
Fretland, AJ; Glenn, KJ; Hussain, S; Palacios, M; Parrott, N; Reddy, MB; Tuerck, D; Vazvaei, F; Yu, LJ; Zhi, J1
Esfandiari, A; Hawthorne, TA; Lunec, J; Nakjang, S1
Assouline, S; Blotner, S; Chen, G; Chen, LC; Dickinson, MJ; Drummond, M; Hashemyan, M; Jukofsky, L; Kasner, M; Kelly, KR; Lee, JH; Martinelli, G; Middleton, SA; Nichols, G; Pierceall, WE; Reis, B; Rueger, R; Seiter, K; So, WV; Theron, M; Vey, N; Yee, K; Yoon, SS; Zhong, H1
Bacac, M; Dangl, M; Friess, T; Herter, S; Herting, F; Klein, C; Muth, G; Sulcova, J; Umana, P1
Edmondson, RJ; Lunec, J; Zanjirband, M1
Birzele, F; Dangl, M; Friess, T; Kiialainen, A; Lehmann, C1
Algeo, MP; Chaire, V; Derieppe, MA; Italiano, A; Laroche-Clary, A; Loarer, FL1
Gonelli, A; Secchiero, P; Tisato, V; Voltan, R; Zauli, G1
Aviles-Padilla, K; Barbieri, E; Chakraborty, R; Chen, Z; Kim, ES; Lakoma, A; Molenaar, JJ; Moreno-Smith, M; Nikzad, R; Paust, S; Schild, L; Scorsone, KA; Sheehan, V; Shohet, JM; Tao, L; Vasudevan, SA; Zhang, Y1
Friess, T; Herting, F; Klein, C; Middleton, S; Umaña, P1
Andrew Johnson, C; Ayers, GD; Chen, SC; Cobb, P; Flaherty, D; Higgins, B; Johnson, DB; Johnston, JN; Kelley, MC; Malikayil, K; Raman, D; Richmond, A; Saleh, N; Vara, BA; Vilgelm, AE1
Andreeff, M; Konopleva, M; Leverson, JD; Mu, H; Nichols, G; Pan, R; Reed, JC; Ruvolo, V1
Aptullahoglu, E; Esfandiari, A; Ho, YH; Lovat, P; Lunec, J; Mahdi, AK; Wang, N; Wu, CE1
Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J1
Blotner, S; Chen, LC; Ferlini, C; Zhi, J1
Chen, L; Esfandiari, A; Hogarty, MD; Lunec, J; Reaves, W; Tweddle, DA; Vu, A1
Chang, Y; Ding, K; Guo, H; Hao, P; Li, L; Li, Z; Ni, Y; Xu, Y; Zhang, ZM; Zhu, D1
Castro, J; Heam, K; Heightman, TD; Lebraud, H; Lunec, J; Newell, DR; Noble, RA; Phillips, N; Wedge, SR; Zhao, Y1
Diodone, R; Fishlock, D; Hildbrand, S; Kuhn, B; Mössner, C; Peters, C; Rege, PD; Rimmler, G; Schantz, M1
Bendszus, M; Berberich, A; Breckwoldt, MO; Ciprut, S; Fischer, M; Hielscher, T; Hucke, N; Kessler, T; Lemke, D; Oezen, I; Platten, M; Pusch, S; Ruebmann, P; Sahm, F; Schmitt, LM; Thomé, CM; von Deimling, A; Wick, W1
Feringa, BL; Feringa, FM; Hansen, MJ; Kobauri, P; Medema, RH; Szymanski, W1
Ou Yang, TH; So, WV; Yang, X; Zhi, J1
Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y1
Foucar, CE; Stein, BL1
Natarajan, U; Radhakrishnan, V; Rathinavelu, A; Samuel, S; Venkatesan, T1
Natarajan, U; Radhakrishnan, V; Rasappan, P; Rathinavelu, A; Samuel, S; Venkatesan, T1
Blotner, S; Chen, LC; Da Costa, D; Gleave, M; Jones, R; Pápai, Z; Vazvaei, F; Zhi, J1
Estey, EH; Percival, MM1
Ritchie, EK1
Chen, D; Chen, K; Guan, G; Hu, H; Li, G; Li, W; Qiao, M; Qiu, L; Xin, X; Zhao, X1
Abdul Razak, AR; Blotner, S; Chen, LC; Gore, L; Higgins, B; Miller, WH; Uy, GL; Young, AM1
Assouline, S; Blotner, S; Chen, LC; Higgins, B; Uy, GL; Yee, K; Young, AM1
Corbali, MO; Eskazan, AE1
Crown, J; Duffy, MJ; O'Grady, S; Synnott, NC1
Cui, Y; Rong, F; Zhou, J1
Arango Ossa, JE; Cassinat, B; Dueck, A; Farnoud, N; Hoffman, R; Houldsworth, J; Kiladjian, JJ; Kosiorek, H; Levine, MF; Lu, M; Marcellino, BK; Mascarenhas, J; McGovern, E; Medina-Martinez, J; Mehrotra, M; Patel, M; Rampal, RK; Rossi, M; Verger, E; Zhou, Y1
Assouline, S; Blotner, S; Chen, LC; Dickinson, MJ; Drummond, MW; Higgins, B; Jukofsky, L; Kasner, M; Kelly, KR; Lee, JH; Martinelli, G; Monnet, A; Muehlbauer, S; Nichols, G; Ott, M; Papayannidis, C; Pierceall, WE; Seiter, K; Simon, S; Vey, N; Yee, K; Yoon, SS; Zhi, J1
Alles, LK; Bate-Eya, LT; Dolman, MEM; Egan, DA; Goldsmith, KC; Jonus, HC; Kerstjens, M; Koopmans, B; Koster, J; Lee, JY; Lelieveld, D; Molenaar, JJ; Schild, L; Schubert, NA; Stam, RW; Vernooij, L1
Ayyagari, P; Das, SK; Pollok, KE; Shannon, HE; Smiley, SB; Vannier, MW; Veronesi, MC; Yun, Y1
Abdeldayem, A; Aittokallio, T; Bhatti, MN; Bukhari, S; de Araujo, ED; Gawel, JM; Geletu, M; Gunning, PT; Hassan, MM; Herling, M; Ianevski, A; Israelian, J; Krämer, OH; Manaswiyoungkul, P; Moriggl, R; Mustjoki, S; Nawar, N; Neubauer, HA; Olaoye, OO; Radu, TB; Raouf, YS; Sedighi, A; Shouksmith, AE; Sorger, H; Timonen, S; Toutah, K; von Jan, J1
Bang, YJ; Blay, JY; Blotner, S; Chen, LC; Gietema, JA; Higgins, B; Hirte, HW; Italiano, A; Jamois, C; Mileshkin, LR; Miller, WH; Nichols, GL; Petry, C; Schmitt, C; Siu, LL; Yang, QJ1
Chen, LH; Diplas, BH; Greer, PK; He, Y; Liu, H; Pirozzi, CJ; Waitkus, MS; Xu, C; Yan, H; Zhang, L1
Bellini, M; Burbury, K; El-Galaly, TC; Gerds, A; Gupta, V; Higgins, B; Huw, LY; Jamois, C; Katakam, S; Kovic, B; Maffioli, M; Mascarenhas, J; Mesa, R; Palmer, J; Passamonti, F; Ross, DM; Vannucchi, AM; Wonde, K; Yacoub, A1
Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K1
Beckermann, BM; Catalani, O; Cavenagh, J; Deeren, D; Fenaux, P; Genevray, M; Girshova, L; Jamois, C; Konopleva, MY; Krauter, J; Martinelli, G; Montesinos, P; Muehlbauer, S; Mundt, K; Ott, M; Ottmann, O; Petrini, M; Pigneux, A; Rambaldi, A; Recher, C; Rodriguez-Veiga, R; Röllig, C; Schäfer, JA; Taussig, D; Vey, N; Wei, AH; Yoon, SS1

Reviews

5 review(s) available for 4-aminobenzoic acid and rg7388

ArticleYear
Small-molecule MDM2-p53 inhibitors: recent advances.
    Future medicinal chemistry, 2015, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Imidazoles; Indoles; Models, Molecular; Neoplasms; Oxindoles; para-Aminobenzoates; Piperazines; Protein Interaction Maps; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Small Molecule Libraries; Structure-Activity Relationship; Tumor Suppressor Protein p53

2015
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Journal of hematology & oncology, 2017, 07-03, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Child; Hematologic Neoplasms; Humans; Imidazolines; Indoles; Molecular Targeted Therapy; Nuclear Proteins; para-Aminobenzoates; Protein Interaction Maps; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Signal Transduction; Spiro Compounds; Tumor Suppressor Protein p53

2017
Novel therapeutic approaches in polycythemia vera.
    Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:11

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Half-Life; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; para-Aminobenzoates; Polycythemia Vera; Polyethylene Glycols; Pyrazoles; Pyrimidines; Pyrrolidines; Recombinant Proteins; Salvage Therapy

2018
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019
Targeting p53 for the treatment of cancer.
    Seminars in cancer biology, 2022, Volume: 79

    Topics: Aminoquinolines; Antineoplastic Agents; Cell Cycle Proteins; Humans; Neoplasms; para-Aminobenzoates; Protein Isoforms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Quinuclidines; Thiosemicarbazones; Tumor Suppressor Protein p53

2022

Trials

9 trial(s) available for 4-aminobenzoic acid and rg7388

ArticleYear
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
    Haematologica, 2016, Volume: 101, Issue:5

    Topics: Blast Crisis; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2016
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Humans; Leukemia, Myeloid; Long QT Syndrome; Male; Middle Aged; Neoplasms; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Young Adult

2018
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Cohort Studies; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
    Investigational new drugs, 2020, Volume: 38, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Growth Differentiation Factor 15; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; para-Aminobenzoates; Polyethylene Glycols; Prodrugs; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Treatment Outcome; Tumor Suppressor Protein p53

2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
    Investigational new drugs, 2020, Volume: 38, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; para-Aminobenzoates; Prodrugs; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Young Adult

2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
    Leukemia research, 2021, Volume: 100

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; para-Aminobenzoates; Prognosis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Remission Induction; Tissue Distribution; Young Adult

2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
    Investigational new drugs, 2021, Volume: 39, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
    Blood advances, 2022, 02-22, Volume: 6, Issue:4

    Topics: Humans; Hydroxyurea; Nausea; para-Aminobenzoates; Polycythemia Vera; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Splenomegaly; Vomiting

2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
    Blood advances, 2022, 07-26, Volume: 6, Issue:14

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; para-Aminobenzoates; Pyrrolidines

2022

Other Studies

41 other study(ies) available for 4-aminobenzoic acid and rg7388

ArticleYear
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
    Journal of medicinal chemistry, 2013, Jul-25, Volume: 56, Issue:14

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; Male; Mice; Mice, Inbred C57BL; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2013
Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jul-15, Volume: 20, Issue:14

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Female; Humans; Imidazolines; Mice, Nude; Osteosarcoma; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Xenograft Model Antitumor Assays

2014
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
    British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Neuroblastoma; para-Aminobenzoates; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Spiro Compounds; Tumor Suppressor Protein p53; Verapamil; Vincristine

2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
    Bioorganic & medicinal chemistry, 2014, Aug-01, Volume: 22, Issue:15

    Topics: Apoptosis; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Imidazolines; Indoles; Indolizidines; Molecular Dynamics Simulation; Neoplasms; para-Aminobenzoates; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Spiro Compounds; Tumor Suppressor Protein p53

2014
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:8

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Female; Growth Differentiation Factor 15; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2015
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Oncotarget, 2015, Apr-30, Volume: 6, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neuroblastoma; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2015
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mice; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Sequence Analysis, DNA; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Clone Cells; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imidazoles; Mutation; para-Aminobenzoates; Ploidies; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Sarcoma; Sequence Analysis, RNA; Signal Transduction; Tumor Suppressor Protein p53

2015
Reactivation of p53 via MDM2 inhibition.
    Cell death & disease, 2015, Oct-22, Volume: 6

    Topics: Animals; Apoptosis; Cell Line, Tumor; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Neovascularization, Pathologic; Neuroblastoma; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2015
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
    Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:8

    Topics: Animals; Antineoplastic Agents; Humans; Macaca fascicularis; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2016
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Catalysis; Cell Line, Tumor; Cell Survival; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Mutation; Neoplasms; para-Aminobenzoates; Piperazines; Protein Phosphatase 2C; Proteolysis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitin

2016
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    European journal of haematology, 2016, Volume: 97, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Killer Cells, Natural; Lymphocyte Depletion; Lymphoma, B-Cell; Mice; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Burden; Xenograft Model Antitumor Assays

2016
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Imidazoles; Ovarian Neoplasms; para-Aminobenzoates; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2016
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Journal of hematology & oncology, 2016, 06-28, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Gene Expression Profiling; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; para-Aminobenzoates; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Sequence Analysis, RNA; Sulfonamides; Tumor Suppressor Protein p53

2016
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Journal of hematology & oncology, 2017, 06-19, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Drug Synergism; Female; Humans; Liposarcoma; Mice; Molecular Targeted Therapy; para-Aminobenzoates; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyridines; Pyrrolidines

2017
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Nov-01, Volume: 23, Issue:21

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Neuroblastoma; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017
Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:6

    Topics: Animals; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Therapy, Combination; Humans; Lymphoma, Non-Hodgkin; Mice; para-Aminobenzoates; Pyrrolidines; Sulfonamides; Xenograft Model Antitumor Assays

2018
MDM2 Antagonists Counteract Drug-Induced DNA Damage.
    EBioMedicine, 2017, Volume: 24

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Replication; HCT116 Cells; Humans; Imidazoles; Melanoma; Mice; para-Aminobenzoates; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrrolidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
    Cancer cell, 2017, Dec-11, Volume: 32, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; para-Aminobenzoates; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Sulfonamides; Synthetic Lethal Mutations; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    British journal of cancer, 2018, 02-20, Volume: 118, Issue:4

    Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dipeptides; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Melanoma, Cutaneous Malignant; Mutagenesis, Site-Directed; para-Aminobenzoates; Phosphorylation; Piperazines; Protein Binding; Protein Phosphatase 2C; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Skin Neoplasms; Tumor Suppressor Protein p53

2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3

    Topics: Administration, Oral; Area Under Curve; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Compounding; Drug Interactions; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tablets; Therapeutic Equivalency; Triazoles

2018
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
    International journal of oncology, 2018, Volume: 52, Issue:3

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Imidazoles; Indoles; Mice; Mice, Transgenic; Mutation; N-Myc Proto-Oncogene Protein; Neuroblastoma; para-Aminobenzoates; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Radiation, Ionizing; Signal Transduction; Spiro Compounds; Tumor Suppressor Protein p53

2018
Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
    Angewandte Chemie (International ed. in English), 2018, 07-20, Volume: 57, Issue:30

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Optical Imaging; para-Aminobenzoates; Proteome; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Structure-Activity Relationship; Sulfonamides

2018
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition.
    Bioconjugate chemistry, 2018, 06-20, Volume: 29, Issue:6

    Topics: Boron Compounds; Cell Line, Tumor; Click Chemistry; Cyclooctanes; Fluorescent Dyes; Humans; Molecular Docking Simulation; Optical Imaging; para-Aminobenzoates; Protein Binding; Protein Interaction Maps; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2018
Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition.
    Chimia, 2018, Aug-22, Volume: 72, Issue:7

    Topics: Catalysis; Copper; Cycloaddition Reaction; Hydrolysis; Isomerism; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2018
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 01-01, Volume: 25, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Heterografts; Humans; Insulin-Like Growth Factor Binding Protein 1; Mice; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyridones; Pyrimidinones; Pyrrolidines; Signal Transduction; Tumor Suppressor Protein p53

2019
Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light.
    Journal of the American Chemical Society, 2018, 10-17, Volume: 140, Issue:41

    Topics: Animals; Cell Line, Tumor; Coumarins; Humans; Light; Molecular Docking Simulation; para-Aminobenzoates; Protein Binding; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Transcription Factors; Xenopus laevis; Xenopus Proteins

2018
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:1

    Topics: Glucuronosyltransferase; Humans; Neoplasms; para-Aminobenzoates; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tissue Distribution

2019
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
    International journal of cancer, 2019, 06-15, Volume: 144, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Neuroblastoma; para-Aminobenzoates; Prodrugs; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Random Allocation; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2019
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
    Cells, 2018, 12-22, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; Female; Histone Deacetylase Inhibitors; Humans; Letrozole; MCF-7 Cells; para-Aminobenzoates; Protein Kinases; Pyrrolidines; Receptor-Interacting Protein Serine-Threonine Kinases; Vorinostat

2018
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Medicina (Kaunas, Lithuania), 2019, Jan-29, Volume: 55, Issue:2

    Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Female; Histone Deacetylase Inhibitors; Humans; Male; MCF-7 Cells; para-Aminobenzoates; Prostatic Neoplasms; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53; Vorinostat

2019
Drug development challenges in polycythemia vera.
    Blood, 2019, 08-08, Volume: 134, Issue:6

    Topics: Drug Development; Humans; para-Aminobenzoates; Polycythemia Vera; Pyrrolidines

2019
Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Acta biomaterialia, 2019, Volume: 100

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Body Weight; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dendrimers; Drug Liberation; Female; Gene Transfer Techniques; Human Umbilical Vein Endothelial Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasms; Neovascularization, Physiologic; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2019
Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
    Future oncology (London, England), 2020, Volume: 16, Issue:14

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; para-Aminobenzoates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Recurrence; Retreatment; Treatment Outcome

2020
Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
    Biochemical and biophysical research communications, 2020, 12-17, Volume: 533, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; MAP Kinase Signaling System; Metformin; Mice, Nude; Ovarian Neoplasms; para-Aminobenzoates; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrrolidines; Reactive Oxygen Species; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2020
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.
    Blood advances, 2020, 11-24, Volume: 4, Issue:22

    Topics: Clone Cells; Humans; para-Aminobenzoates; Polycythemia Vera; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

2020
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
    Molecular cancer therapeutics, 2021, Volume: 20, Issue:6

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; High-Throughput Screening Assays; Humans; Mice; Neuroblastoma; para-Aminobenzoates; Proto-Oncogene Proteins c-mdm2; Pyrrolidines

2021
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
    Pharmaceutical research, 2021, Volume: 38, Issue:6

    Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Development; Drug Evaluation, Preclinical; Glioblastoma; Humans; Mice; Micelles; Nanoparticles; Neoplastic Stem Cells; para-Aminobenzoates; Polymers; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Temozolomide

2021
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
    Journal of medicinal chemistry, 2021, 06-24, Volume: 64, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Prolymphocytic, T-Cell; Male; Mice; Molecular Docking Simulation; Molecular Structure; para-Aminobenzoates; Pyrrolidines; Structure-Activity Relationship; Sulfonamides

2021
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Acta neuropathologica communications, 2021, 11-03, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Stem Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diffuse Intrinsic Pontine Glioma; Humans; Mice; para-Aminobenzoates; Protein Phosphatase 2C; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2021
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
    Drug metabolism and disposition: the biological fate of chemicals, 2022, Volume: 50, Issue:3

    Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Isoenzymes; Leukemia, Myeloid, Acute; Models, Biological; para-Aminobenzoates; Pyrrolidines; Risk Assessment

2022